The first patient enrolled in a planned international clinical trial has been treated at HonorHealth Research Institute with a new type of immune therapy for those with a rare muscle-weakness disease ...

Glenmark Therapeutics Inc., USA (Glenmark) is pleased to announce the launch1 of Olopatadine Hydrochloride Ophthalmic ...